undamentalytics Newsletter
Sign in

Ovid Therapeutics Inc. revenue

Ovid Therapeutics Inc.'s revenue was $7.3m in fiscal 2025, up 1181.3% on the year before. Since fiscal 2020 ($12.6m) it has grown at a compound -10.5% a year. Over the last twelve months it was $1.6m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1320820172
Growth on the year before—+>999%−99.3%−73.9%+44.4%+>999%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Ovid Therapeutics Inc. $1.6m -76.2% 99.8%
Absci Corp $1.6m -62.3% -43.3%
Cartesian Therapeutics, Inc. $1.5m 44.0% -68.8%
Dare Bioscience, Inc. $1.4m 4366.5% —
Seres Therapeutics, Inc. $1.9m 100.0% -75.6%
Korsana Biosciences, Inc. $1.9m -12.6% —

Compare with peers

Head to head: ABSI vs OVIDOVID vs RNACDARE vs OVIDMCRB vs OVID

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ovid Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ovid Therapeutics Inc.